{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nusinersen",
    "query": {
      "intervention": "nusinersen"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=nusinersen&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T09:24:17.390Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02292537",
      "title": "A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        },
        {
          "name": "Sham procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 126,
      "start_date": "2014-11-24",
      "completion_date": "2017-02-20",
      "has_results": true,
      "last_update_posted_date": "2021-02-17",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02292537"
    },
    {
      "nct_id": "NCT02052791",
      "title": "An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 47,
      "start_date": "2014-01-31",
      "completion_date": "2017-01-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052791"
    },
    {
      "nct_id": "NCT03709784",
      "title": "Spinraza in Adult Spinal Muscular Atrophy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Muscular Atrophy",
        "Spinal Muscular Atrophy Type II",
        "Spinal Muscular Atrophy Type 3"
      ],
      "interventions": [
        {
          "name": "Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care",
          "type": "DRUG"
        },
        {
          "name": "One time survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 148,
      "start_date": "2018-08-16",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Owosso",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709784"
    },
    {
      "nct_id": "NCT02594124",
      "title": "A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 292,
      "start_date": "2015-11-04",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02594124"
    },
    {
      "nct_id": "NCT06955897",
      "title": "Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-04-24",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06955897"
    },
    {
      "nct_id": "NCT06555419",
      "title": "A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscular Atrophy, Spinal"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        },
        {
          "name": "ThecaFlex DRx System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2025-01-16",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 10,
      "location_summary": "Orange, California • Palo Alto, California • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06555419"
    },
    {
      "nct_id": "NCT05067790",
      "title": "A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "15 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-01-21",
      "completion_date": "2027-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Owosso",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05067790"
    },
    {
      "nct_id": "NCT05522361",
      "title": "Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Risdiplam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinic for Special Children",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-11-06",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 1,
      "location_summary": "Strasburg, Pennsylvania",
      "locations": [
        {
          "city": "Strasburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05522361"
    },
    {
      "nct_id": "NCT02462759",
      "title": "A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 21,
      "start_date": "2015-08-19",
      "completion_date": "2018-09-24",
      "has_results": true,
      "last_update_posted_date": "2021-02-17",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462759"
    },
    {
      "nct_id": "NCT05386680",
      "title": "Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "OAV101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 27,
      "start_date": "2023-01-12",
      "completion_date": "2024-11-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-02T09:24:17.390Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Norfolk, Virginia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05386680"
    }
  ]
}